Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR) The Avicenna Medical Journal
Roxanne, Olivia Geraldine
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Treatment Outcome of Remdesivir Compared to Favipiravir on Moderate Symptoms COVID-19 Arifin, Arief Riadi; Yunus, Faisal; Patrama, Satria; Putra, Muhammad Ryan Adi; Roxanne, Olivia Geraldine
The Avicenna Medical Journal Vol. 4 No. 1 (2023): The Avicenna Medical Journal
Publisher : Faculty of Medicine, UIN Syarif Hidayatullah Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15408/avicenna.v4i1.31132

Abstract

Remdesivir and Favipiravir have been widely used as antiviral agents in treating COVID-19. However, studies providing head on comparison of treatment outcomes between the two antiviruses are rare. The aim of this study is to compare the treatment outcome of Remdesivir and Favipiravir in moderate symptoms COVID-19. Subjects were divided into two groups based on received antivirus during COVID-19 treatment in the hospital, Remdesivir group and Favipiravir group. Post-treatment outcome was measured with three indicators: symptom improvement, negative conversion of RT-PCR, and radiological improvement. Outcomes of both groups were compared with chi square test with Remdesivir serves as a risk factor and Favipiravir as control. Out of a total of 130 subjects, 65 received Remdesivir, and 65 received Favipiravir. Post-treatment RT-PCR and radiologic examination were performed on a median of Day-10 hospitalization. RT-PCR conversion to negative was significantly more likely in Remdesivir group (RR: 1,917, 95% Cl 1,044 – 3,518, p = 0.047, chi square test). There was no significant difference between Remdesivir group and Favipiravir group in symptom improvement on Day-5 (RR 0.941, 95% Cl 0.776 – 1,141), nor Day-7 (RR 1.020, 95% Cl 0.855 – 1.216). There was also no significant difference in radiological improvement (RR 0.855, 95% Cl 0.712 – 1.026). Administering remdesivir to COVID-19 patients significantly increased the occurrence of negative RT-PCR conversion after therapy compared to standard favipiravir therapy.
P/F Ratio is a Better Predictor for Non-Invasive Ventilation Failure and Length of Stay in Patients with Community-Acquired Pneumonia Hapsari, Brigitta Anindita Devi; Roxanne, Olivia Geraldine; Reviono, Reviono; Adhiputri, Artrien; Apriningsih, Hendrastutik; Rahayu, Nur Indah; Vagheggini, Guido
Jurnal Respirasi Vol. 10 No. 1 (2024): January 2024
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v10-I.1.2024.42-49

Abstract

Introduction: Community-acquired pneumonia (CAP) can deteriorate into respiratory failure requiring immediate ventilatory intervention. This study compared the performance of the PaO2/FiO2 (P/F) ratio, the ratio of oxygen saturation (ROX) index, and the heart rate, acidosis, consciousness, oxygenation, and respiratory rate (HACOR) score in predicting non-invasive ventilation (NIV) failure and length of hospital stay in patients diagnosed with CAP. Methods: This study was conducted at Universitas Sebelas Maret Hospital, Surakarta, from March to September 2023. All patients diagnosed with CAP who were eligible for NIV were recruited. Each patient's age, sex, comorbidities, vital signs, pneumonia severity index (PSI), blood urea, bilirubin, hematocrit, blood sodium, P/F ratio, ROX index, and HACOR score were measured within the first 24 hours of NIV. Subsequently, the correlations between these variables and NIV failure (intubation or mortality) and length of hospital stay were assessed. Results: The P/F ratio, ROX index, and HACOR score were not correlated with intubation or length of stay. The P/F ratio was correlated with mortality (p = 0.040), whereas the other scores were not. Higher body temperature was correlated with intubation (p = 0.032). PSI was correlated with both mortality (p = 0.033) and length of hospital stay (p = 0.009). Conclusion: The P/F ratio is superior to the ROX index and HACOR score in predicting mortality in patients with pneumonia-related respiratory failure treated with NIV. Since it is simple and accessible, measuring the P/F ratio within the first 24 hours of NIV is recommended to identify a patient's risk of NIV failure and apply appropriate monitoring.
Co-Authors Adhiputri, Artrien Apriningsih, Hendrastutik Arifin, Arief Riadi Faisal Yunus Hapsari, Brigitta Anindita Devi Patrama, Satria Putra, Muhammad Ryan Adi Rahayu, Nur Indah Reviono Reviono Vagheggini, Guido